Inventor · disambiguated record
Steven Victor O'Neil
Also filed as: O'NEIL STEVEN V · O'NEIL STEVEN VICTOR
28 granted patents·12 pending applications·166 citations·filing 2000–2024
96Inventor score
Top patents by PatentIndex Score
40 records- 0194US9107923B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Aug 18, 2015·11 cites·30 claims
- 0293US9527831B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2014·Granted Dec 27, 2016·13 cites·30 claims
- 0393US9139561B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Sep 22, 2015·8 cites·30 claims
- 0493US7326705B2Heterocyclic sodium/proton exchange inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Feb 5, 2008·24 cites·18 claims
- 0592US6887870B1Heterocyclic sodium/proton exchange inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2000·Granted May 3, 2005·51 cites·28 claims
- 0691US9822097B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2016·Granted Nov 21, 2017·6 cites·15 claims
- 0790US9845301B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2016·Granted Dec 19, 2017·8 cites·9 claims
- 0890US8822494B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2013·Granted Sep 2, 2014·12 cites·54 claims
- 0989US2024317713A1Heteroaromatic compounds and their use as dopamine d1 ligandsPFIZER·Filed 2024·Application pending·0 cites
- 1087US9617275B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Apr 11, 2017·5 cites·18 claims
- 1187US9133190B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2014·Granted Sep 15, 2015·8 cites·60 claims
- 1286US10093655B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2017·Granted Oct 9, 2018·3 cites·20 claims
- 1384US10421744B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2018·Granted Sep 24, 2019·2 cites·20 claims
- 1483US10329308B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2018·Granted Jun 25, 2019·2 cites·23 claims
- 1582US10428034B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2017·Granted Oct 1, 2019·3 cites·18 claims
- 1682US9527843B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Dec 27, 2016·3 cites·14 claims
- 1779US10858373B2Heterocyclic spiro compounds as MAGL inhibitorsPFIZER·Filed 2019·Granted Dec 8, 2020·1 cites·17 claims
- 1877US11964961B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2021·Granted Apr 23, 2024·0 cites·20 claims
- 1974US11014909B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2020·Granted May 25, 2021·0 cites·22 claims
- 2074US10696658B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2019·Granted Jun 30, 2020·0 cites·13 claims
- 2171US9868744B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Jan 16, 2018·1 cites·14 claims
- 2266US10723711B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2019·Granted Jul 28, 2020·0 cites·18 claims
- 2366US9745317B2Heterocyclic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Aug 29, 2017·1 cites·22 claims
- 2465US6630506B1Bicyclic acyl guanidine sodium/proton exchange inhibitors and methodBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Oct 7, 2003·2 cites·26 claims
- 2564US2024238425A1HSD17B13 Inhibitors and/or DegradersPFIZER·Filed 2023·Application pending·0 cites
- 2663US10626125B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2019·Granted Apr 21, 2020·0 cites·23 claims
- 2762US2017165270A1Heteroaromatic Compounds and their Use as Dopamine D1 LigandsPFIZER·Filed 2017·Application pending·0 cites
- 2862US2024150334A1Hsd17b13 inhibitors and/or degradersPFIZER·Filed 2023·Application pending·0 cites
- 2962US2015291625A1Heteroaromatic Compounds and their Use as Dopamine D1 LigandsPFIZER·Filed 2013·Application pending·0 cites
- 3061US7138395B2Interleukin-1β converting enzyme inhibitorsPROCTER & GAMBLE·Filed 2003·Granted Nov 21, 2006·2 cites·69 claims
- 3160US2018200253A1Heteroaromatic Compounds and their Use as Dopamine D1 LigandsPFIZER·Filed 2018·Application pending·0 cites
- 3260US2024366598A1Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereofPFIZER·Filed 2024·Application pending·0 cites
- 3357US2018346477A1Heteroaromatic compounds and their use as dopamine d1 ligandsPFIZER·Filed 2018·Application pending·0 cites
- 3456US10077272B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2017·Granted Sep 18, 2018·0 cites·19 claims
- 3556US2018208608A1Heterocyclic spiro compounds as magl inhibitorsPFIZER·Filed 2018·Application pending·0 cites
- 3647US2021309669A1Heterocyclic Spiro Compounds As MAGL InhibitorsPFIZER·Filed 2019·Application pending·0 cites
- 3743US7041696B2Interleukin-1β converting enzyme inhibitorsPROCTER & GAMBLE·Filed 2003·Granted May 9, 2006·0 cites·44 claims
- 3842US7001899B2Interleukin converting enzyme inhibitorsPROCTER & GAMBLE·Filed 2003·Granted Feb 21, 2006·0 cites·41 claims
- 3938US2010273772A1Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)WYETH LLC·Filed 2010·Application pending·0 cites
- 4035US2016016907A1Pyridine derivatives as muscarinic m1 receptor positive allosteric modulatorsPFIZER·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven Victor O'Neil files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →